Benefits
Gentler on the stomach? Head-to-head trials disagree
Marketed as causing fewer GI side effects than ferrous salts, but trials disagree. In a randomized trial of 72 people with iron-deficiency anemia, GI effects were slightly more frequent on a ferrous fumarate product; in a double-blind trial in 80 young children, diarrhea was more common on this complex than on ferrous sulfate drops (58% vs 35%). Designed for delayed release in small intestine reduces gastric irritation.
Higher Elemental Iron Per Capsule
Niferex® Forte contains 150 mg elemental iron per capsule — among the highest single-dose iron content. Reduces pill burden vs multiple ferrous sulfate or gluconate tablets.
No Stomach Acid Required (Unlike Carbonate)
Iron polysaccharide complex is dispersed in polysaccharide matrix — does not require gastric acid for dissolution. Theoretically advantageous for PPI users.
Pediatric Liquid Forms Available
Iron polysaccharide complex liquid (Nu-Iron® Pediatric) is available for pediatric iron supplementation when liquid forms preferred. In a double-blind trial of drops in children aged 9 to 48 months, it raised hemoglobin less and caused more diarrhea than ferrous sulfate drops.
Marketing-Driven Popularity
Despite lower effectiveness, iron polysaccharide complex is frequently prescribed/recommended by clinicians who prioritize tolerability over hemoglobin response. Important to understand the trade-off.
Less fatigue when low iron is corrected (shown with ferrous sulfate)
Low iron stores can cause tiredness. In two placebo-controlled trials in tired, non-anemic women, ferrous sulfate (80 mg iron daily, 4 or 12 weeks) eased fatigue more than placebo, mainly when ferritin was low. This complex is untested for tiredness. In iron-deficient heart-failure patients, 300 mg a day for 16 weeks gave no significant gain in exercise capacity; in young children it rebuilt iron stores more slowly than ferrous sulfate.
Mechanism of action
Ferric (Fe³⁺) Form Requires Reduction
Iron polysaccharide complex provides ferric iron (Fe³⁺) — must be reduced to ferrous (Fe²⁺) before absorption via DMT1. This reduction step is rate-limiting and often inefficient — major reason for poor bioavailability vs ferrous salts (which provide directly-absorbable Fe²⁺).
Delayed Polysaccharide Release
Iron is bound within polysaccharide matrix that gradually disperses in small intestine — slower iron release vs ferrous salts. Reduces gastric mucosal irritation but also reduces concentration available for absorption.
Lower Bioavailability (Liu 2004)
In a head-to-head RCT in iron-deficiency anemia patients, a ferrous fumarate combination product raised hemoglobin 2.84 g/dL vs iron polysaccharide complex 0.60 g/dL at 12 weeks (significantly greater). The Niferex group also had less ferritin and MCV improvement. Major effectiveness gap despite equal elemental iron dosing.
Standard Iron Functions Once Absorbed
Once iron is absorbed (less efficiently than from ferrous salts), it functions normally in hemoglobin synthesis, etc.
Clinical trials
Open-label clinical trial comparing equivalent daily doses of iron polysaccharide complex (150 mg elemental iron) vs a ferrous fumarate combination product for 12 weeks in IDA patients (Liu et al. 2004)
IDA patients.
Ferrous fumarate group — hemoglobin increase 2.84 g/dL; iron polysaccharide complex group — hemoglobin increase only 0.60 g/dL (a significantly greater increase in the ferrous fumarate group). Substantial bioavailability/effectiveness gap. Polysaccharide complex group also had less ferritin, less MCV improvement. Polysaccharide complex's tolerability advantage came at substantial cost to therapeutic effectiveness.
Tolerability comparisons of iron polysaccharide complex vs ferrous sulfate in clinical practice.
Iron-supplementing patients.
No survey or controlled study is cited for a GI tolerability advantage. In a double-blind randomized trial in 80 young children, diarrhea was more common on iron polysaccharide complex than on ferrous sulfate (58% vs 35%). But effectiveness lower (Liu 2004).